Other Respiratory Program

About Vast Therapeutics

Vast Therapeutics is a private, pre-revenue biotech focused on a significant unmet need in chronic respiratory diseases, which affect over 500 million people globally. The company has advanced its lead candidate into Phase 1 clinical trials and has secured non-dilutive grant funding and Orphan Drug Designation, validating its approach. Its pipeline targets specific infections and inflammatory pathways in conditions like cystic fibrosis and bronchiectasis, aiming to improve quality of life and reduce hospitalizations. The company is currently raising capital through a public Reg CF funding round.

Therapeutic Areas